Jove
Visualize
Contact Us

Related Experiment Videos

Antibacterial agents in pediatrics

J J LiPuma1, T L Stull

  • 1Medical College of Pennsylvania, Philadelphia, USA.

Infectious Disease Clinics of North America
|September 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Longitudinal bacterial prevalence in cystic fibrosis airways: Fact and artifact.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2023
Same author

Cystic Fibrosis Mice Develop Spontaneous Chronic <i>Bordetella</i> Airway Infections.

Journal of infectious pulmonary diseases·2018
Same author

Draft Genome Sequence of the Pandoraea apista LMG 16407 Type Strain.

Genome announcements·2015
Same author

Rhizobium radiobacter bacteremia in a neonate.

Infection·2011
Same author

'Haptoglobin concentrations in preterm and term newborns'.

Journal of perinatology : official journal of the California Perinatal Association·2011
Same author

Induction of immune response to the 17 kDa OMPA Burkholderia cenocepacia polypeptide and protection against pulmonary infection in mice after nasal vaccination with an OMP nanoemulsion-based vaccine.

Medical microbiology and immunology·2009
Same journal

Prevention and Control of Clostridioides difficile Infection for the Infectious Diseases Clinician.

Infectious disease clinics of North America·2026
Same journal

Infection Control Strategies to Prevent Emergence and Transmission of Resistant Gram-Negative Bacteria.

Infectious disease clinics of North America·2026
Same journal

Preventing the Spread of Tuberculosis in Health Care Settings.

Infectious disease clinics of North America·2026
Same journal

Threats to Success: Principles of Infection Prevention and Control in Health Care Settings, Part 2: Device and Pathogen Management.

Infectious disease clinics of North America·2026
Same journal

Ventilator-Associated Events: Surveillance and Prevention.

Infectious disease clinics of North America·2026
Same journal

Nosocomial Fungal Infections: Epidemiology, Control Strategies, and Prevention of Candida and Other Yeasts.

Infectious disease clinics of North America·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

This review examines age-related pharmacokinetics and antibacterial agent toxicity in pediatric infectious disease therapy. It highlights new oral cephalosporins and macrolides for children.

Area of Science:

  • Pediatric Pharmacology
  • Infectious Disease Therapeutics
  • Antimicrobial Agents

Background:

  • Antibacterial agent efficacy in children depends on unique pharmacokinetic profiles and toxicity.
  • Understanding age-related pharmacokinetic principles is crucial for safe and effective pediatric treatment.
  • Infectious diseases in children require careful consideration of drug selection and dosage.

Purpose of the Study:

  • To review age-related pharmacokinetic principles relevant to pediatric drug therapy.
  • To discuss the use of specific therapeutic antibacterial agents in children.
  • To emphasize the application of novel antibiotics, including oral cephalosporins and macrolides, in pediatric populations.

Main Methods:

  • Review of existing literature on pediatric pharmacokinetics.

Related Experiment Videos

  • Analysis of therapeutic applications of antibacterial agents in pediatric patients.
  • Focus on new antibiotic classes, specifically oral cephalosporins and macrolides.

    • Main Results:

    • Pharmacokinetics in children exhibit significant age-related variations.
    • Specific antibacterial agents demonstrate varying utility and safety profiles in pediatric populations.
    • Newer oral cephalosporins and macrolides offer promising therapeutic options for pediatric infections.

    Conclusions:

    • Age-specific pharmacokinetic data are essential for optimizing antibacterial therapy in children.
    • Careful selection and monitoring of antibacterial agents are necessary to ensure efficacy and minimize toxicity.
    • The use of novel oral antibiotics warrants further investigation for expanded pediatric application.